THIS DOCUMENT IS OF A MERELY INFORMATIVE NATURE. THIS DOCUMENT IS NEITHER A REGISTRATION DOCUMENT NOR A PROSPECTUS AND MUST NOT BE TREATED AS AN OFFER OF ANY KIND. IT IS NOT TO BE RELEASED, DISTRIBUTED OR PUBLISHED DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE THEREOF WOULD BE UNLAWFUL.

TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 24 September 2018

In compliance with the disclosure requirements provided for article 228 of the Securities Market Act and article 17 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014, on market abuse, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby informs the National Securities Market Commission of the following:

RELEVANT EVENT

INTENTION TO CONDUCT CAPITAL INCREASE

ROVI today announces its intention to increase its share capital in order to raise gross proceeds of up to €80 million by means of monetary contributions and excluding the preferential subscription rights of ROVI's shareholders (the "**Capital Increase**"). Proceeds will be used to partly finance the Phase III clinical testing of Doria® and other expenses related to Doria® until its commercialization, if approved, to finance, in whole or in part, the Phase I clinical testing of Letrozol ISM®[1], to support the ongoing commercialization of its enoxaparin biosimilar Becat® and for general corporate purposes, which may include acquisitions. Total financing needs for the ISM® platform are expected to be approximately €150 million through 2021.

In addition to the Capital Increase, ROVI expects to fund this research and development and additional working capital needs through internal cash flow generation and existing debt capacity.

[1] ISM® stands for "In-Situ Microparticles" and refers to ROVI's sustained release injectable technology.

THIS DOCUMENT IS OF A MERELY INFORMATIVE NATURE. THIS DOCUMENT IS NEITHER A REGISTRATION DOCUMENT NOR A PROSPECTUS AND MUST NOT BE TREATED AS AN OFFER OF ANY KIND. IT IS NOT TO BE RELEASED, DISTRIBUTED OR PUBLISHED DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE THEREOF WOULD BE UNLAWFUL.

The final decision regarding whether or not to execute the Capital Increase is expected to be taken by the Board of Directors of ROVI during the fourth quarter of 2018, subject to market conditions. Bookbuilding may commence at short notice.

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, said "*Since our IPO in 2007, ROVI has consistently delivered on its long-term strategic objectives, notably expanding our LMWH franchise with the successful rollout of Hibor®, and the development and launch of our enoxaparin biosimilar Becat®, while continuing to drive the growth of our Spanish specialty pharma and toll manufacturing businesses. We are very excited to have reached several major achievements including the ongoing European commercialisation rollout of Becat® and the final development phase of Doria, the lead programme of our ISM® platform. We believe that the proposed capital increase would enable us to embrace this new phase of growth and keep our balance sheet strong to execute on other opportunities for the benefit of our shareholders.*"

Company Information

ROVI is a fully-integrated European specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of pharmaceuticals and contrast imaging agents. The Company has leveraged its unparalleled know-how of the low molecular weight heparin or "LMWH" market to develop its two flagship products, bemiparin, which is marketed directly in Spain under the name Hibor®, and the enoxaparin biosimilar Becat®. ROVI is also the partner of choice for global pharmaceutical players in Spain and markets a diversified portfolio of both proprietary and in-licensed products through an approximately 250-person specialized sales force.

The Company, in a continuous international expansion process, has established subsidiaries in Germany, the United Kingdom, Italy and France, and has a diversified marketing portfolio of more than 40 products. Further, the Company utilizes state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing value-added services to leading international pharmaceutical companies, such as the manufacture of pre-filled syringes for which ROVI is one of the leading global manufacturers in terms of number of units manufactured.

ROVI's research and development strategy is primarily focused on addressing currently unmet medical needs by expanding applications for its ISM® technology, which currently has two clinical programs in various stages of development.

Diversified European specialty pharmaceutical company with three growth drivers

Leveraging over 70 years of experience in developing heparin-based drugs and its vertical integration, ROVI's specialty pharmaceuticals business comprises (a) its leading proprietary LMWH franchise, anchored by bemiparin and its enoxaparin biosimilar, Becat®, (b) a leading Spanish specialty pharmaceutical business, which the Company aims to expand across its other European sales offices in the coming years, and (c) its high-value-added toll manufacturing business.

Leading proprietary LMWH franchise: Bemiparin is ROVI's internally developed flagship heparin product; it is the second-leading LMWH in Spain, with a market share of approximately 32% as of June 2018 according to IQVIA. Outside Spain, bemiparin is marketed in 56 countries throughout-licensing agreements, and registration is pending in 14 additional countries. Bemiparin generated sales of €84 million in 2017. ROVI launched its internally developed enoxaparin biosimilar Becat® in Germany in September 2017, in the United Kingdom in March 2018, in Italy in April 2018 and in Spain (under the Enoxaparina ROVI® name) in September 2018. In addition, the Company has launched its enoxaparin biosimilar in France in September 2018 pursuant to an agreement with Biogaran. The Company has established subsidiaries in Germany, the United Kingdom, France and Italy and plans to establish another subsidiary in Poland. Together with Spain and Portugal, these countries represent approximately 75% of the European enoxaparin market. In addition, ROVI plans for further expansion in Europe, building a pan-European infrastructure with the potential to be leveraged for further growth. In addition to Germany, the United Kingdom, Italy and Spain, Becat® has been approved in three additional countries for direct marketing, in 19 countries for out-licensed marketing, and has pending approval for out-licensing in 46 additional countries. ROVI has already signed out-licensing agreements with respect to 45 countries to distribute its enoxaparin biosimilar, including an agreement with Hikma with respect to the Middle East and North Africa, and another agreement with Sandoz with respect to 14 countries/regions.

Leading Spanish specialty pharmaceutical business: ROVI's leadership and long-standing experience in the Spanish specialty pharmaceuticals market positions the Company as a partner of choice for global pharmaceutical companies looking to market their products in Spain. ROVI has a portfolio of 16 proprietary products and 27 in-licensed products, supported by one of the largest specialty pharmaceuticals sales forces in Spain, with approximately 250 employees, and local regulatory expertise.

High-value-added toll manufacturing services: Through its toll manufacturing business, ROVI manufactures pre-filled syringes and oral forms and suppositories to leading global pharmaceutical companies. The Company has established a customer-oriented business model, offering high-value-added services, in particular with respect to the manufacture of pre-filled syringes, which drives significant barriers to entry in the Company's toll manufacturing business. ROVI operates two injectables plants, and is a global leader in the manufacture of pre-filled syringes, one of its fastest growing products, and vials. The Company relies on a strong regulatory track record, with multiple GMP and FDA approvals. In 2017, ROVI produced products that were sold in over 40 countries.

Proprietary ISM technology platform opens up new avenues of growth

The innovative ISM® technology is a drug-release platform internally developed and patented by ROVI, which allows for the sustained release of active compounds administered by injection. The product candidates using the ISM® technology are Doria® and Letrozole ISM®, which are in Phase III and Phase I clinical trials respectively. The success of this technology lies in the following key aspects: (i) highly efficient drug retention; (ii) excellent stability of the active substance; (iii) high level of control of the initial release of the drug; (iv) avoidance of refrigerated storage; (v) flexible posology of one to six months; and (vi) patent protection until 2033. The ISM® technology was developed with a view to overcome the disadvantages of existing prolonged-release oral or injectable formulations by providing greater simplicity, efficacy and stability. ROVI expects potential for wide applicability of this technology to new chronic therapeutic areas, including psychiatry and oncology, and believes that its vertical integration and expertise in pre-filled syringe manufacturing puts the Company in a privileged position to take advantage of its patent-protected ISM® technology.

Doria®, ROVI's proprietary risperidone LAI, is the lead candidate from the Company's ISM® platform and is currently in Phase III testing. LAIs are increasingly becoming the standard treatment of schizophrenia, and they have benefits compared with oral antipsychotics in terms of cost. Doria® leverages the ISM® technology with the proven efficacy and safety of risperidone, which has shown clinical outcomes. If approved, Doria® could capture a share of an attractive market in which approximately 20% of U.S. and EU schizophrenia patients are treated with oral risperidone. ROVI expects to receive the final Phase III data readout at the end of the second quarter of 2019.

Sound financial policy supported by strong track record

Between 2015 and 2017, ROVI's revenues grew at a CAGR of approximately 6.0%. In 2017, the Company generated revenues of €277 million, and adjusted EBITDA of €30 million. Over the past three years, ROVI has maintained double-digit adjusted EBITDA margins despite significant R&D investment into its ISM technology and the development of Doria®. The Company's net financial debt (available-for-sale financial assets/equity securities plus deposits and cash and cash equivalents minus short term and long term financial debt) at the end of 2017 was €1.1 million. For over a decade, ROVI's senior management team has established a track record of growth and value creation, leading to the Company's market capitalization as of September 18, 2018 increasing by 69% since its IPO.

ROVI's Board of Directors has agreed to consider adjusting or suspending the current dividend distribution policy, subject to shareholder approval, if necessary to support the Company's growth strategy.

Offering Details

The Capital Increase would be executed by means of monetary contributions through the issue of new ordinary shares with a nominal value of €0.06 per share (the "**Offer Shares**") to raise gross proceeds of up to €80 million. If launched, the Capital Increase is expected to be completed during the fourth quarter of 2018 and would exclude the preferential subscription rights of ROVI's existing shareholders. Bookbuilding may commence at short notice.

THIS DOCUMENT IS OF A MERELY INFORMATIVE NATURE. THIS DOCUMENT IS NEITHER A REGISTRATION DOCUMENT NOR A PROSPECTUS AND MUST NOT BE TREATED AS AN OFFER OF ANY KIND. IT IS NOT TO BE RELEASED, DISTRIBUTED OR PUBLISHED DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE THEREOF WOULD BE UNLAWFUL.

In connection with the Capital Increase, Jefferies International Limited is acting as Sole Global Coordinator and Bookrunner, Fidentiis Equities S.V., S.A. is acting as co-bookrunner and Renta 4 Banco, S.A. is acting as placement agent.

The Company and its majority shareholder, Norbel Inversiones S.L., are expected to undertake not to issue or sell shares (lock-up), subject to customary exceptions, during a period of 180 days from the date of the admission to trading of the Offer Shares on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges.

Juan López-Belmonte Encina
Chief Executive Officer and General Manager
Laboratorios Farmacéuticos Rovi, S.A.

THIS DOCUMENT IS OF A MERELY INFORMATIVE NATURE. THIS DOCUMENT IS NEITHER A REGISTRATION DOCUMENT NOR A PROSPECTUS AND MUST NOT BE TREATED AS AN OFFER OF ANY KIND. IT IS NOT TO BE RELEASED, DISTRIBUTED OR PUBLISHED DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE THEREOF WOULD BE UNLAWFUL.

This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States of America ("U.S."), Canada, Australia, Japan, South Africa or any other jurisdiction in which the distribution or release would be unlawful.

The information contained herein shall not constitute an offer to sell, or a solicitation of offers to purchase or subscribe for, securities in the U.S. The securities referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended, and may not be offered, exercised or sold in the U.S. absent registration or an applicable exemption from registration requirements. There is no intention to register any portion of the offering in the U.S. or to conduct a public offering of securities in the U.S. This document does not solicit money, securities or any other type of consideration and, if any money, securities or other type of consideration is sent in response hereto, it will not be accepted.

The issue or sale of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. ROVI assumes no responsibility in the event there is a violation by any person of such restrictions.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the offering memorandum to be issued by the Company in connection with the Capital Increase. The information in this announcement is subject to change.

ROVI has not authorized any offer to the public of securities in any Member State of the European Economic Area. With respect to each Member State of the European Economic Area and which has implemented the Prospectus Directive (each, a "Relevant Member State"), no action has been undertaken nor will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in Article 2(1)(e) of the Prospectus Directive; or (b) in any other circumstances which do not require the publication by ROVI of a prospectus pursuant to Article 3 of the Prospectus Directive. For the purposes of this paragraph, the expression an "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as

to enable an investor to decide to exercise, purchase or subscribe for the securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010/73/EU Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State.

In the United Kingdom, this document, and any other material in relation to the securities referred to herein, is directed only at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) persons who are high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates will only be available to and will only be engaged in with, relevant persons. Any person who is not a relevant person must not act or rely on this document or any of its contents.

Jefferies International Limited, which is regulated by the Financial Conduct Authority, and Fidentiis Equities, S.V., S.A. and Renta 4 Banco, S.A., which are regulated by the *Comisión Nacional del Mercado de Valores*, are acting exclusively for ROVI and no-one else in connection with the Capital Increase. They will not regard any other person as their respective clients in relation to the Capital Increase and will not be responsible to anyone other than ROVI for providing the protections afforded to their respective clients, nor for providing advice in relation to the Capital Increase, the contents of this announcement or any transaction, arrangement or other matter referred to herein.

In connection with the Capital Increase, Jefferies International Limited, Fidentiis Equities, S.V., S.A. and Renta 4 Banco, S.A. and any of their affiliates, may take up a portion of the Offer Shares as a principal position and in that capacity may retain, purchase, sell, offer to sell for their own accounts such Offer Shares. Accordingly, references in this announcement, to the Offer Shares being issued, offered, subscribed, acquired, placed or otherwise dealt in should be read as including any issue or offer to, or subscription, acquisition, placing or dealing by, Jefferies International Limited, Fidentiis Equities, S.V., S.A. and Renta 4 Banco, S.A. and any of their affiliates acting in such capacity. In addition, Jefferies International Limited, Fidentiis Equities, S.V., S.A. and Renta 4 Banco, S.A. and any of their affiliates may enter into financing arrangements (including swaps or contracts for differences) with investors in connection with which Jefferies International Limited, Fidentiis Equities,

THIS DOCUMENT IS OF A MERELY INFORMATIVE NATURE. THIS DOCUMENT IS NEITHER A REGISTRATION DOCUMENT NOR A PROSPECTUS AND MUST NOT BE TREATED AS AN OFFER OF ANY KIND. IT IS NOT TO BE RELEASED, DISTRIBUTED OR PUBLISHED DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE THEREOF WOULD BE UNLAWFUL.

S.V., S.A. and Renta 4 Banco, S.A. and any of their affiliates may from time to time acquire, hold or dispose of shares of the Company. Jefferies International Limited, Fidentiis Equities, S.V., S.A. and Renta 4 Banco, S.A. do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

None of Jefferies International Limited, Fidentiis Equities, S.V., S.A. and Renta 4 Banco, S.A. or any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

Information to distributors: Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the securities the subject of the offering have been subject to a product approval process, which has determined that such securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the securities may decline and investors could lose all or part of their investment; the securities offer no guaranteed income and no capital protection; and an investment in the securities is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offering. Furthermore, it is noted that, notwithstanding

the Target Market Assessment, Jefferies International Limited, Fidentiis Equities, S.V., S.A. and Renta 4 Banco, S.A. will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the securities. Each distributor is responsible for undertaking its own target market assessment in respect of the securities and determining appropriate distribution channels.

This document includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations and projections about its future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies, plans, opportunities, achievements, trends and the industry in which it operates. Forward-looking statements involve all matters that are not historical fact. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results of operations, financial condition, liquidity, performance, prospects, strategies or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events described in this document may not occur. Additional risks that the Company may currently deem immaterial or that are not presently known to it could also cause the forward-looking events discussed in this document not to occur. Except as otherwise required by Spanish and other applicable securities law and regulations or by any applicable stock exchange regulations, the Company undertakes no obligation to update publicly or revise publicly any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason after the date of this document. Given the uncertainty inherent in forward-looking statements, prospective investors should not place undue reliance on these statements.